ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...

The traditional gold standard of clinical trials with a randomized, placebo-controlled design involving hundreds of patients ...

Across multiple studies, the motivation for using cannabis predicts outcomes as strongly as frequency of use. Among emerging ...

Mistletoe therapy may improve the QOL of patients with cancer; however, evidence does not support a survival benefit, ...

This reduces delays and improves results. For example, some platforms offer support for early-stage research and help teams ...

Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced a poster ...

Latest stories about Social Media on Business Insider ...

Nature Didn’t Design the Perfect Stinger. Time and Friction Did. In A Nutshell Scientists may have misattributed the ...

"We snorted tons of m*** off a toilet that day." View Entire Post › ...

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical ...

Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + ...

Obesity is linked to increased cancer risk through inflammation, metabolic dysfunction, and immune changes. Dr. Jennifer ...